Eribulin mesylate reduces tumor microenvironment abnormality by vascular remodeling in preclinical human breast cancer models-Reference-Cited by-同舟云学术

Eribulin mesylate reduces tumor microenvironment abnormality by vascular remodeling in preclinical human breast cancer models

Published:2014-09-16 Issue:10 Volume:105 Page:1334-1342
ISSN:1347-9032
Container-title:Cancer Science
language:en
Short-container-title:Cancer Sci

Author:

Funahashi Yasuhiro¹,Okamoto Kiyoshi²,Adachi Yusuke²,Semba Taro²,Uesugi Mai³,Ozawa Yoichi²,Tohyama Osamu³,Uehara Taisuke³,Kimura Takayuki³,Watanabe Hideki³,Asano Makoto²,Kawano Satoshi²,Tizon Xavier⁴,McCracken Paul J.¹,Matsui Junji²,Aoshima Ken³,Nomoto Kenichi⁵,Oda Yoshiya¹

Affiliation:

1. Biomarkers and Personalized Medicine Core Function Unit Eisai Inc. Andover Massachusetts USA

2. Oncology Product Creation Unit Eisai Co., Ltd. Tsukuba Ibaraki Japan

3. Biomarkers and Personalized Medicine Core Function Unit Eisai Co., Ltd. Tsukuba Ibaraki Japan

4. Oncodesign S.A. Dijon Cedex France

5. Oncology Product Creation Unit Eisai Inc. Andover Massachusetts USA

Publisher

Wiley

Subject

Cancer Research,Oncology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/cas.12488

Reference39 articles.

1. Microtubules as a target for anticancer drugs

2. Microtubule-binding agents: a dynamic field of cancer therapeutics

3. Clinical translation of angiogenesis inhibitors

4. The microtubule‐affecting drug paclitaxel has antiangiogenic activity;Belotti D;Clin Cancer Res,1996

5. Comparison of antiangiogenic activities using paclitaxel (taxol) and docetaxel (taxotere)

Cited by 215 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting the tumour vasculature: from vessel destruction to promotion;Nature Reviews Cancer;2024-08-29

2. Combination of eribulin and anlotinib exerts synergistic cytotoxicity in retroperitoneal liposarcoma by inducing endoplasmic reticulum stress;Cell Death Discovery;2024-08-08

3. Eribulin versus S-1 as first or second-line chemotherapy to assess health-related quality of life and overall survival in HER2-negative metastatic breast cancer (RESQ study): a non-inferiority, randomised, controlled, open-label, phase 3 trial;eClinicalMedicine;2024-08

4. Research progress in tumor angiogenesis and drug resistance in breast cancer;Cancer Biology & Medicine;2024-06-25

5. Eribulin in breast cancer: Current insights and therapeutic perspectives;World Journal of Experimental Medicine;2024-06-20